Acacia
- Generic Name
- Acacia
- Drug Type
- Biotech
- CAS Number
- 9000-01-5
- Unique Ingredient Identifier
- 5C5403N26O
- Background
Acacia allergenic extract is used in allergenic testing.
ACTG Launches ACACIA Trial in Africa to Evaluate HIV Cure Strategy
• The ACTG has initiated the ACACIA (A5417) study, a Phase 2 trial, to assess the safety and efficacy of broadly neutralizing antibodies (bNAbs) in HIV treatment.
• ACACIA will evaluate the combination of 3BNC117-LS and 10-1074-LS with antiretroviral therapy (ART) in adults living with HIV across four African countries.
• The trial includes an analytic treatment interruption (ATI) phase to determine if the intervention can control HIV in the absence of ART, a key step in HIV cure research.
• ACACIA aims to optimize the therapeutic benefit of bNAbs by administering them when viral load is high and assessing their long-lasting immunologic effects.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath